Alan and Kathie Stross
Alan and Kathie Stross were dedicated supporters of the DHT. They were compassionate people who believed that medical research should continue without the use of animals.
To ensure the DHT could continue to fund cruelty-free medical research projects, they pledged to leave us a legacy donation. Leaving a gift in their will has resulted in Alan and Kathie Stross leaving a true legacy that will keep their memories alive.
After their deaths, in honour of their legacy gift, and in accordance with their wishes, the DHT has created the Alan and Kathie Stross summer fellowships fund and launched the Animal Replacement Centre of Excellence (The ARC).
Alan and Kathie Stross summer fellowships offer funding for research projects lasting up to 3 months, and aimed at recently graduated researchers who will investigate a project where the research is primarily focused on the replacement of primates, cats and dogs.
The scheme is aimed at supporting the next generation of research scientists, creating the opportunity for them to experience and actively participate in the development of innovative approaches to help further populate the ‘toolbox’ of non-animal technologies.
Additionally, in conjunction with the DHT's summer studentships, PhD studentships and post-doctoral research positions, the Alan and Kathie Stross summer fellowship scheme will allow the DHT to further embed non-animal medical research as an option for the next generation of research scientists.
The Animal Replacement Centre of Excellence (The ARC) is a joint venture between Queen Mary University of London’s Blizard Institute and the Dr Hadwen Trust to advance cancer research without the use of animals.
The ARC, funded by the legacy left by Alan and Kathie Stross, is a very exciting initiative dedicated to non-animal research into skin, breast and prostate cancer: human models for human disease.
Professor Mike Philpott and Dr Adrian Biddle will lead this focused drive to develop the most robust and applicable, non-animal research into human cancer.
The ARC will serve as a focal point for innovative and cutting-edge technology development and extend QMUL’s portfolio of non-animal research. The success of this initiative could have global implications for the advancement of non-animal medical research.